Novavax reported $-228852000 in EBITDA for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US USD -55733000 15.79M
AstraZeneca AZN:LN USD 3.32B 283M
Astrazeneca AZN:US USD 3.32B 283M
Dynavax Technologies DVAX:US USD 64.6M 1.88M
GlaxoSmithKline GSK:LN GBP 1.6B 1.76B
Mannkind MNKD:US USD -7696000 1.94M
Minerva Neurosciences NERV:US USD -5063000 142K
Moderna Inc MRNA:US USD 1.66B 381M
Novartis NVS:US USD 4.5B 193M
Novavax NVAX:US USD -228852000 110.01M
Peregrine Pharmaceuticals PPHM:US USD 4.64M 5.5M
Pfizer PFE:US USD 6.94B 3.94B
Sarepta Therapeutics SRPT:US USD -96280000 24.37M
Tg Therapeutics TGTX:US USD -51989000 17.1M